



March 27, 2025  
JCR Pharmaceuticals Co., Ltd.

**JCR Revises Full-Year Consolidated Forecast for FY2024**

**Mar. 27, 2025** -- [JCR Pharmaceuticals Co., Ltd.](https://www.jcr-pharm.co.jp) (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced today that the Company made the following revisions to the consolidated earnings forecasts for the fiscal year ended March 31, 2025 disclosed on January 31, 2025 based on the current business performance.

There are no changes to the previously announced dividend forecast.

Looking ahead to the fiscal year ending March 2026, JCR expects to remain profitable at all levels from operating profit onward. Specific figures will be disclosed in the financial results announcement scheduled for May 13, 2025.

1. Revision of consolidated financial forecasts for the fiscal year ended March 31, 2025

(Unit: Millions of yen)

	Net Sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share (yen)
Previously announced forecasts (A)	39,000	1,400	750	2,200	17.77
Revised forecasts (B)	33,000	(6,000)	(6,700)	(4,300)	(34.73)
Change (B-A)	(6,000)	(7,400)	(7,450)	(6,500)	—
Change (%)	(15.4) %	—	—	—	—
Actual Results of the previous fiscal year	42,871	7,531	7,246	5,507	44.13

2. Reason for the revision

Net sales have been adjusted downward by 6 billion yen to 33 billion yen, as a licensing agreement that had been expected to close during the current fiscal year is now unlikely to be finalized before year-end.

Cost of sales and R&D expenses have increased following a closer review of inventories, including raw materials and investigational drugs, with write-offs for unused items to be recorded in the current fiscal year. These adjustments are expected to impact cost of sales by 200 million yen and R&D expenses by 1.1 billion yen.

In addition, JCR had planned to record approximately 1.5 billion yen in extraordinary income tied to a government subsidy related to the construction of its API facility at the Kobe Science Park Center (completed in November 2022). However, the official approval of the subsidy is

now expected to occur in the next fiscal year. As a result, the anticipated gain will not be reflected in this term's results.

As a result, operating profit has been revised downward by 7.4 billion yen to operating loss of 6 billion yen, ordinary profit by 7.45 billion yen to ordinary loss of 6.7 billion yen, and profit attributable to owners of parent by 6.5 billion yen to loss attributable to owners of parent of 4.3 billion yen.

#### **About JCR Pharmaceuticals Co., Ltd.**

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and belief – benefit all our stakeholders, including patients, partners, and employees. For more information, please visit

<https://www.jcrpharm.co.jp/en/site/en/>.

#### Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

[ir-info@jp.jcrpharm.com](mailto:ir-info@jp.jcrpharm.com)

###